Quarterly report pursuant to Section 13 or 15(d)

EQUITY TRANSACTIONS (Details Narrative)

v3.21.2
EQUITY TRANSACTIONS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Jul. 28, 2021
Jun. 17, 2021
Mar. 09, 2021
Apr. 30, 2019
Mar. 31, 2021
Jul. 31, 2021
May 31, 2021
Apr. 30, 2021
Jul. 31, 2020
Jul. 28, 2020
May 27, 2016
Class of Stock [Line Items]                      
Preferred Stock, Shares Authorized           10,000,000   10,000,000      
Preferred Stock, Par or Stated Value Per Share           $ 0.0001   $ 0.0001      
Common stock, authorized before amendment to Certificate of Incorporation                     150,000,000
Common stock, authorized               300,000,000     300,000,000
Warrant terms           3 years 3 months 18 days          
Warrant [Member]                      
Class of Stock [Line Items]                      
Warrant terms           5 years     2 years 6 months    
Exercise price (in dollars per share)   $ 6.25               $ 3.00  
[custom:NumberOfStockRepurchase]   61,250       727,917          
Warrant [Member] | D P L [Member]                      
Class of Stock [Line Items]                      
Exercise price (in dollars per share) $ 1.50                    
[custom:NumberOfStockRepurchase] 1,333,333                    
[custom:NumberOfStockRepurchaseValue] $ 2,000,000                    
A L S F [Member]                      
Class of Stock [Line Items]                      
Shares purchase price       $ 15,000,000              
Warrant terms       12 months              
Securities Purchase Agreements [Member] | A L S F [Member]                      
Class of Stock [Line Items]                      
Number of shares purchase       10,000,000              
Shares purchase price       $ 15,000,000              
Shares purchase price (in dollars per share)       $ 1.50              
Securities Purchase Agreements [Member] | A L S F [Member] | Warrant [Member]                      
Class of Stock [Line Items]                      
Number of shares purchase       5,000,000              
Warrant terms       5 years              
Exercise price (in dollars per share)       $ 3.00              
Securities Purchase Agreements [Member] | Digital Power Lending [Member]                      
Class of Stock [Line Items]                      
Number of shares issued         6,666,667            
Proceeds from sale of equity         $ 10,000,000            
Shares issued price per share         $ 1.50 $ 1.50 $ 666,667        
Proceeds from related party     $ 4,000,000                
Advance from related parties     $ 1,800,000                
Description of purchase agreement terms         DPL purchased an additional (i) 1,333,333 shares of Common Stock upon approval by the FDA of our IND for our Phase Ia clinical trials for a purchase price of $2 million, and (ii) will purchase 2,666,667 shares of the Company’s Common Stock upon the completion of these Phase Ia clinical trials for a purchase price of $4 million. The Company further agreed to issue to DPL warrants to purchase a number of shares of Common Stock equal to 50% of the shares of Common Stock purchased under the securities purchase agreement at an exercise price of $3.00 per share            
Securities Purchase Agreements [Member] | Digital Power Lending [Member] | Final Tranche [Member]                      
Class of Stock [Line Items]                      
Proceeds from related party         $ 4,000,000            
Additional right to invest         $ 10,000,000 $ 10,000,000          
Securities Purchase Agreements [Member] | Ault Global [Member] | Convertible Promissory Note [Member]                      
Class of Stock [Line Items]                      
Number of shares issued     2,666,667                
Shares value surrender for cancellation     $ 50,000                
Series A Preferred Stock [Member]                      
Class of Stock [Line Items]                      
Preferred Stock, Shares Authorized           8,640,000          
Preferred Stock, Par or Stated Value Per Share           $ 0.0001   $ 0.0001      
[custom:PreferredStockSharesDesignated-0]           1,360,000   1,360,000      
Description of dividend rights           no dividend rights except as may be declared by the Board in its sole and absolute discretion, out of funds legally available for that purpose          
Preferred stock voting rights           entitled to fifty (50) non-cumulative votes per share on all matters presented to the Company’s stockholders for action          
Preferred stock terms of conversion           the right to convert their shares into shares of Common Stock at any time at a conversion rate equal to twenty (20) shares of Common Stock for every one (1) Series A Preferred Share